IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. It designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. The company offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. It also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include Hummingbird Quad ICP monitoring with drainage (H610), and Hummingbird Solo ICP monitoring (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. It markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was incorporated in 2011 and is headquartered in Stockholm, Sweden.
Show more...
CEO
Mr. Will Martin
직원
44
국가
스웨덴
ISIN
SE0008321202
WKN
000A2H5NT
상장
0 Comments
생각을 공유하기
FAQ
오늘 Irras AB 주가는 얼마인가요?▼
IRRAF의 현재 가격은 $0.53 USD이며, 지난 24시간 동안 -15.36% 하락했습니다. 차트에서 Irras AB 주가 흐름을 자세히 살펴보세요.
Irras AB의 주식 심볼은 무엇인가요?▼
거래소에 따라 주식 심볼이 다를 수 있습니다. 예를 들어, 거래소에서는 Irras AB 주식이 IRRAF 심볼로 거래됩니다.
Irras AB의 시가총액은 얼마인가요?▼
오늘 Irras AB의 시가총액은 600.53M입니다
Irras AB의 지난 분기 실적은 어땠나요?▼
IRRAF의 지난 분기 실적은 주당 -0.05 USD로, 예상치 해당 없음 USD 대비 해당 없음의 서프라이즈를 기록했습니다. 다음 분기 예상 실적은 주당 해당 없음 USD입니다.